Pareto Securities and Analysguiden publish research reports; Pareto increases price target to SEK 79
Hørsholm, Denmark, December 9, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in December, following the publication of initial results for the phase II testing of ABNCoV2. Pareto reiterated its ‘buy’ rating and increased its target price SEK 79 per share, based on an increased likelihood of approval.Both research reports are available on the Analyst Reports page of ExpreS[2]ion’s